Regeneron Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe Disease
- Conditions
- Interventions
- First Posted Date
- 2021-10-18
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 25
- Registration Number
- NCT05081388
- Locations
- 🇺🇸
PNS Clinical Research, LLC, Mission Viejo, California, United States
🇺🇸PharmaTex Research, LLC, Amarillo, Texas, United States
🇺🇸Ark Clinical Research, Long Beach, California, United States
A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults
- First Posted Date
- 2021-10-12
- Last Posted Date
- 2023-07-24
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 66
- Registration Number
- NCT05074433
- Locations
- 🇺🇸
Innovative Research of West Florida, Inc., Clearwater, Florida, United States
🇺🇸Great Lakes Clinical Trials - Ravenswood, Chicago, Illinois, United States
🇺🇸Institute of Human Virology, Baltimore, Maryland, United States
A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis
- Conditions
- Interventions
- First Posted Date
- 2021-10-07
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 235
- Registration Number
- NCT05070858
- Locations
- 🇺🇸
HonorHealth Neurology 2018, Scottsdale, Arizona, United States
🇺🇸University of California Irvine, Irvine, California, United States
🇺🇸University of Southern California, Los Angeles, California, United States
COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age
- First Posted Date
- 2021-08-05
- Last Posted Date
- 2023-03-06
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 7
- Registration Number
- NCT04992273
- Locations
- 🇺🇸
Advanced Research Center, Inc, Anaheim, California, United States
🇺🇸Stony Brook University Hospital, Stony Brook, New York, United States
🇺🇸SUNY Upstate Medical University, Syracuse, New York, United States
Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer
- First Posted Date
- 2021-07-29
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 237
- Registration Number
- NCT04982224
- Locations
- 🇺🇸
University of California Irvine School of Medicine - Suite 400, Room 407, Orange, California, United States
🇺🇸University of Colorado Hospital Anshutz Outpatient Pavillion, Denver, Colorado, United States
🇺🇸Johns Hopkins Hospital - Clinical Study Location - Skip Viragh Outpatient Cancer Building, Baltimore, Maryland, United States
A Study to Examine the Efficacy and Safety of Anti-Fel d 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic Rhinitis Who Live With a Cat
- Conditions
- Interventions
- First Posted Date
- 2021-07-29
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 446
- Registration Number
- NCT04981717
- Locations
- 🇺🇸
Integrated Research of Inland, Inc, Riverside, California, United States
🇺🇸Allergy and Asthma Specialists PSC, Owensboro, Kentucky, United States
🇺🇸Allergy Partners of Western North Carolina, Asheville, North Carolina, United States
Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)
- Conditions
- First Posted Date
- 2021-07-13
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 717
- Registration Number
- NCT04959448
- Locations
- 🇺🇸
John Hopkins University School Of Medicine, Baltimore, Maryland, United States
🇺🇸Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
🇺🇸The University of Chicago Medical Center UCMC Duchossois Center for Advanced Medicine DCAM, Chicago, Illinois, United States
A Study to Examine the Safety, Tolerability and Biological Effects of Single Doses of Subcutaneously and Intravenously Administered Pozelimab as Monotherapy and in Combination With Single Doses of Subcutaneously Administered Cemdisiran in Adult Japanese Healthy Volunteers
- First Posted Date
- 2021-06-25
- Last Posted Date
- 2022-07-06
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 30
- Registration Number
- NCT04940364
- Locations
- 🇬🇧
Regeneron Research Site, London, United Kingdom
A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer
- First Posted Date
- 2021-06-07
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 77
- Registration Number
- NCT04916002
- Locations
- 🇺🇸
University of California, Los Angeles, California, United States
🇺🇸Ohio State University, Columbus, Ohio, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Pozelimab and Cemdisiran Combination Therapy in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Switch From Eculizumab Therapy
- Conditions
- Interventions
- First Posted Date
- 2021-05-17
- Last Posted Date
- 2023-06-13
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 6
- Registration Number
- NCT04888507
- Locations
- 🇬🇧
Regeneron Study Site, Leeds, United Kingdom